Approval · Notice of Compliance 7866 · 2006
INVIRASE: Notice of Compliance 7866
Issued March 31, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7866
- Date
- March 31, 2006
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New 500 mg tablet and additional dosing regimen
- Therapeutic class
- HIV protease inhibitor/antiretroviral agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INVIRASE | Not yet assigned | — |
| INVIRASE | 02279320 | Cancelled Post Market |
Medicinal ingredients
- SAQUINAVIR MESYLATE 500 MG per TAB
- SAQUINAVIR MESYLATE 200 MG per CAP